Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

Abstract

In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.

Keywords

• approved drugs
• baricitinib
• FDA
• Janus kinases
• protein kinase inhibitor
• rheumatoid arthritis